Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024 Mar 27; 15(1):2691.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Female
Humans
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Triple Negative Breast Neoplasms

authors with profiles

Rita Nanda